These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 21414671)

  • 1. En route to new blockbuster anti-histamines: surveying the offspring of the expanding histamine receptor family.
    Leurs R; Vischer HF; Wijtmans M; de Esch IJ
    Trends Pharmacol Sci; 2011 Apr; 32(4):250-7. PubMed ID: 21414671
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Major advances in the development of histamine H4 receptor ligands.
    Smits RA; Leurs R; de Esch IJ
    Drug Discov Today; 2009 Aug; 14(15-16):745-53. PubMed ID: 19477292
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Histamine H3 and H4 receptors as novel drug targets.
    Tiligada E; Zampeli E; Sander K; Stark H
    Expert Opin Investig Drugs; 2009 Oct; 18(10):1519-31. PubMed ID: 19758107
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular determinants of ligand binding modes in the histamine H(4) receptor: linking ligand-based three-dimensional quantitative structure-activity relationship (3D-QSAR) models to in silico guided receptor mutagenesis studies.
    Istyastono EP; Nijmeijer S; Lim HD; van de Stolpe A; Roumen L; Kooistra AJ; Vischer HF; de Esch IJ; Leurs R; de Graaf C
    J Med Chem; 2011 Dec; 54(23):8136-47. PubMed ID: 22003888
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Histamine H4 receptor ligands and their potential therapeutic applications.
    Kiss R; Keseru GM
    Expert Opin Ther Pat; 2009 Feb; 19(2):119-35. PubMed ID: 19441913
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The challenge of drug discovery of a GPCR target: analysis of preclinical pharmacology of histamine H3 antagonists/inverse agonists.
    Hancock AA
    Biochem Pharmacol; 2006 Apr; 71(8):1103-13. PubMed ID: 16513092
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stereochemical diversity-oriented conformational restriction strategy. Development of potent histamine H3 and/or H4 receptor antagonists with an imidazolylcyclopropane structure.
    Watanabe M; Kazuta Y; Hayashi H; Yamada S; Matsuda A; Shuto S
    J Med Chem; 2006 Sep; 49(18):5587-96. PubMed ID: 16942032
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Histamine H3 and H4 receptor affinity of branched 3-(1H-imidazol-4-yl)propyl N-alkylcarbamates.
    Łazewska D; Wiecek M; Ligneau X; Kottke T; Weizel L; Seifert R; Schunack W; Stark H; Kieć-Kononowicz K
    Bioorg Med Chem Lett; 2009 Dec; 19(23):6682-5. PubMed ID: 19846299
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tritium-labeled N(1)-[3-(1H-imidazol-4-yl)propyl]-N(2)-propionylguanidine ([(3)H]UR-PI294), a high-affinity histamine H(3) and H(4) receptor radioligand.
    Igel P; Schnell D; Bernhardt G; Seifert R; Buschauer A
    ChemMedChem; 2009 Feb; 4(2):225-31. PubMed ID: 19101971
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and structure-activity relationships of conformationally constrained histamine H(3) receptor agonists.
    Kitbunnadaj R; Zuiderveld OP; De Esch IJ; Vollinga RC; Bakker R; Lutz M; Spek AL; Cavoy E; Deltent MF; Menge WM; Timmerman H; Leurs R
    J Med Chem; 2003 Dec; 46(25):5445-57. PubMed ID: 14640553
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Agonist/antagonist modulation in a series of 2-aryl benzimidazole H4 receptor ligands.
    Savall BM; Edwards JP; Venable JD; Buzard DJ; Thurmond R; Hack M; McGovern P
    Bioorg Med Chem Lett; 2010 Jun; 20(11):3367-71. PubMed ID: 20452213
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selective histamine H₃ and H₄ receptor agonists exert opposite effects against the gastric lesions induced by HCl in the rat stomach.
    Coruzzi G; Adami M; Pozzoli C; de Esch IJ; Smits R; Leurs R
    Eur J Pharmacol; 2011 Nov; 669(1-3):121-7. PubMed ID: 21839070
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Keynote review: histamine H3 receptor antagonists reach out for the clinic.
    Celanire S; Wijtmans M; Talaga P; Leurs R; de Esch IJ
    Drug Discov Today; 2005 Dec; 10(23-24):1613-27. PubMed ID: 16376822
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The future antihistamines: histamine H3 and H4 receptor ligands.
    Yu F; Bonaventure P; Thurmond RL
    Adv Exp Med Biol; 2010; 709():125-40. PubMed ID: 21618893
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The histamine H(3) receptor: a target for new drugs].
    Arrang JM
    Ann Pharm Fr; 2003 May; 61(3):173-84. PubMed ID: 12714930
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent advances in histamine H3 receptor antagonists/inverse agonists.
    Łazewska D; Kieć-Kononowicz K
    Expert Opin Ther Pat; 2010 Sep; 20(9):1147-69. PubMed ID: 20716022
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Receptor-specific functional efficacies of alkyl imidazoles as dual histamine H3/H4 receptor ligands.
    Kottke T; Sander K; Weizel L; Schneider EH; Seifert R; Stark H
    Eur J Pharmacol; 2011 Mar; 654(3):200-8. PubMed ID: 21237145
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Piperazine modification in 2,4,6-triaminopyrimidine derivatives as histamine H4 receptor ligands.
    Schreeb A; Walter M; Odadzic D; Schwed JS; Weizel L; Stark H
    Pharmazie; 2013 Jul; 68(7):521-5. PubMed ID: 23923631
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Compared pharmacology of human histamine H3 and H4 receptors: structure-activity relationships of histamine derivatives.
    Gbahou F; Vincent L; Humbert-Claude M; Tardivel-Lacombe J; Chabret C; Arrang JM
    Br J Pharmacol; 2006 Apr; 147(7):744-54. PubMed ID: 16432504
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Histamine H3 and H4 receptors are expressed on distinct endocrine cell types in the rat fundic mucosa.
    Morini G; Becchi G; Shenton FC; Chazot PL; Grandi D
    Inflamm Res; 2008; 57 Suppl 1():S57-8. PubMed ID: 18345490
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.